-
– Development of Lysine-Targeting, Cell-Active Covalent Inhibitors (CIs) with High Potency and Selectivity (MOE T2)". Human kinases and epigenetic proteins are important therapeutic targets. Recent development
-
proteins (NMRC)". Human kinases and epigenetic proteins are important therapeutic targets. Recent development of selective and potent inhibitors of proteins has yielded remarkable results in disease
-
sensitivity, selectivity, and reproducibility, and exploring potential applications. Act as a key resource for the research team by offering expertise in organic and polymer chemistry. Support and guide
-
these values. For more information about the College, please visit https://www.yale-nus.edu.sg. Personal Data Protection Act (PDPA) Candidates should understand that by sharing information with Yale-NUS